62nd ASH Annual Meeting & Exposition Dec 5 - Dec 8, 2020 Supporting Materials Microenvironmental Immune Senescence and Exhaustion in AML Associate w Response to Flotetuzumab 2.9 MB TP53 Abnormalities - Response to Flotetuzumab in AML (Rutella) 1 MB Flotetuzumab (CD123 x CD3) as Salvage Therapy for PIF and ER AML (Aldoss) 976.1 KB Flotetuzumab Upregulates MHC Class II Expression on AML (Rimando) 696.9 KB Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in AML (Rutella) 22.4 MB Phase 1 Study of MGD013 (Tebotelimab, PD-1 x LAG-3) in Patients with RR DLBCL (Wang) 912.2 KB Prophylactic Ruxolitinib for CRS in RR AML Pts Treated w Flotetuzumab (Uy) 653 KB
Microenvironmental Immune Senescence and Exhaustion in AML Associate w Response to Flotetuzumab 2.9 MB
Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in AML (Rutella) 22.4 MB